Despite a broader trend of disagreement among national pharma regulators over instances for which to issue drug safety alerts, there appears to be some degree of convergence on warnings regarding certain insomnia drugs.
The US Food and Drug Administration issued a drug safety communication on 30 April announcing that it would be adding boxed warnings to the labels and Medication Guides of certain Rx insomnia drugs following reports of serious injury or death